Single award · contract
Medicine Company - Advance the Development of a Portfolio of Anti-Infective Programs
Award ID: HHSO100201600026C
A single federal award, with both ends of the trail linked.
$98.1M
Total award value
Award HHSO100201600026C is a contract from the Department of Health and Human Services, $98.1M obligated, FY2016 to FY2030, for Medicine Company - Advance the Development of a Portfolio of Anti-Infective Programs. The work is performed in New Jersey. It is classified as PSC AN13 (Health R&D Services; Health Care Services; Experimental Development) and NAICS 541711 (Research and Development in Biotechnology). Source
Description
The Medicine Company - Advance the Development of a Portfolio of Anti-Infective Programs. Igf::ot::igf
Award details
Award typeContract
PIIDHHSO100201600026C
Action date2016
Period168 mo
Awarding agencyDepartment of Health and Human Services →
RecipientOutside our Phase 1 contractor set: see methodology
Place of performanceNew Jersey →
CategoryPSC AN13NAICS 541711
Competed?Not recordedSource
Total (exact)$98,144,230
More from Department of Health and Human Services
awarded 2025$110.4B
awarded 2024$100.1B
awarded 2023$92B
awarded 2022$80.5B
awarded 2021$80.5B
Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are Source; figures we calculate are Computed; links we infer (corporate parents, districts, similar contractors, connections between records) are Inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.